Disease · MONDO_0012105
granulomatosis with polyangiitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. granulomatosis with polyangiitis. Diseases, record MONDO_0012105. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0012105
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
GPA, Wegener granulomatosis, Wegener's granulomatosis, Wegener's syndrome, granulomatosis - Wegener's, necrotizing respiratory granulomatosis, pauci-immune glomerulonephritis associated with granulomatosis with polyangiitis
- Open Targets
- Highest stage of its drugs
- Approval, for 2 of its 31 drugs, from DailyMed, EMA Human Drugs, FDA and PMDA
- Open Targets
Drugs31
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| RITUXIMAB | CHEMBL1201576 | Antibody | Approval | DailyMed, EMA Human Drugs and PMDA | 19 | 12 | 12 | Drugs and targets |
| AVACOPAN | CHEMBL3989871 | Small molecule | Approval | EMA Human Drugs and FDA | 5 | 3 | 3 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 6 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| METHOTREXATE | CHEMBL34259 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| AZATHIOPRINE | CHEMBL1542 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| MYCOPHENOLATE MOFETIL | CHEMBL1456 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| MEPOLIZUMAB | CHEMBL2108429 | Antibody | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| GUSPERIMUS | CHEMBL406117 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 2 | 2 | Drugs and targets |
| ABATACEPT | CHEMBL1201823 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 31
See all 31 drugsTargets22
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 5 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| IL2RA | Interleukin-2 receptor | 2 | Interleukin-2 receptor agonist; Interleukin-2 receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3559 | Drugs and targets |
| IL2RB | Interleukin-2 receptor | 2 | Interleukin-2 receptor agonist; Interleukin-2 receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3560 | Drugs and targets |
| IL2RG | Interleukin-2 receptor | 2 | Interleukin-2 receptor agonist; Interleukin-2 receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3561 | Drugs and targets |
| IL5 | Interleukin-5 | 2 | Interleukin-5 inhibitor | Phase 3 | https://conductscience.org/library/genes/3567 | Drugs and targets |
| MS4A1 | B-lymphocyte antigen CD20 | 2 | B-lymphocyte antigen CD20 binding agent | Approval | https://conductscience.org/library/genes/931 | Drugs and targets |
| TNF | Tumor necrosis factor | 2 | TNF-alpha inhibitor | Phase 2/3 | https://conductscience.org/library/genes/7124 | Drugs and targets |
| C5 | Complement C5 | 1 | Complement C5 inhibitor | Phase 2 | https://conductscience.org/library/genes/727 | Drugs and targets |
| C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 1 | C5a anaphylatoxin chemotactic receptor antagonist | Approval | https://conductscience.org/library/genes/728 | Drugs and targets |
| CD80 | T-lymphocyte activation antigen CD80 | 1 | T-lymphocyte activation antigen CD80 inhibitor | Phase 3 | https://conductscience.org/library/genes/941 | Drugs and targets |
1 to 10 of 22
See all 22 targetsTrials45
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00104299 | Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis | Phase 2/3 | 197 | 2011-08-25 | Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis | RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01663623 | Belimumab in Remission of VASculitis | Phase 3 | 106 | 2018-04-17 | Vasculitis | AZATHIOPRINE, BELIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01613599 | An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis | 100 | 2016-08-17 | Granulomatosis With Polyangiitis, Microscopic Polyangiitis | RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT03298061 | Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 | Phase 3 | 100 | 2024-03-12 | Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis | MEPOLIZUMAB | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT03895801 | Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis. | Phase 2 | 57 | 2022-08-25 | Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA) | VILOBELIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00530075 | Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis | Phase 2 | 45 | 2017-03-06 | Wegener's Granulomatosis | GUSPERIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT01750697 | A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis | Phase 2 | 25 | 2019-06-26 | Granulomatosis With Polyangiitis | RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00468208 | Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis | Phase 1/2 | 20 | 2013-11-26 | Wegener's Granulomatosis | ABATACEPT | Its record names the disease | ClinicalTrials.gov |
| NCT03712345 | Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA | Phase 2 | 20 | 2022-05-26 | Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA) | VILOBELIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02654379 | Observational Study Evaluating Rituximab Use and Use of the Patient Alert Card in Participants Receiving Rituximab Infusion for a Non-Oncology Indication at Infusion Centers in Europe | 1,408 | Off-Label Use | RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 45
See all 45 trialsComparisons in its trials8
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Rituximab vs Control Group: Percentage of Participants Who Have a BVAS/WG Score of 0 and Have Successfully Completed the Glucocorticoid Taper by 6 Months Post-randomization | 62 of 99 | 51 of 98 | 197 | NCT00104299 | Trial comparisons |
| Rituximab vs Control Group: Disease Remission | 63 of 99 | 52 of 98 | 197 | NCT00104299 | Trial comparisons |
| Rituximab vs Control Group: serious adverse events | 60 of 99 | 47 of 98 | 197 | NCT00104299 | Trial comparisons |
| Belimumab 10 mg/kg vs Placebo: deaths from any cause | 1 of 53 | 0 of 52 | 105 | NCT01663623 | Trial comparisons |
| Belimumab 10 mg/kg vs Placebo: Number of Participants With Major Relapse During the Double-blind Phase of the Study | 1 of 53 | 0 of 52 | 105 | NCT01663623 | Trial comparisons |
| Belimumab 10 mg/kg vs Placebo: serious adverse events | 18 of 53 | 16 of 52 | 105 | NCT01663623 | Trial comparisons |
| Remission Induction Phase: Rituximab vs Overall Follow-up Phase: Rituximab: deaths from any cause | 0 of 25 | 0 of 25 | 50 | NCT01750697 | Trial comparisons |
| Remission Induction Phase: Rituximab vs Overall Follow-up Phase: Rituximab: serious adverse events | 7 of 25 | 12 of 25 | 50 | NCT01750697 | Trial comparisons |
Papers from its trials38
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0012105
GET https://conductscience.org/api/diseases/v1/MONDO_0012105/drugs?page=2